Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
H. Lundbeck A/S
Age
18–80
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy subjects:
\- Men and women ≥18 and ≤55 years of age with a body mass index (BMI) ≥18 and ≤32 kg/m2 (non-Japanese subjects) and ≥18 and ≤28 kg/m2 (Japanese subjects)
Patients with Parkinson's disease:
Men and women with a clinical diagnosis of idiopathic Parkinson's disease, Hoehn and Yahn (H\&Y, stage 1-3)
For a minimum of three months prior to enrolment, Parkinson's disease symptoms have been stable and is anticipated to be stable during the study duration as judged by the PI
If on Parkinson's disease treatment the dose must be stable for a minimum of three months prior to enrolment and is anticipated to be stable during the study duration as judged by the PI
≥40 and ≤80 years of age
BMI ≥18 and ≤35 kg/m2
You may not be if
Atypical Parkinsonism
Clinically relevant structural brain abnormality, as assessed using MRI
Mild cognitive impairment, measured as a Montreal cognitive assessment (MoCA) score =\<21
Any past or current treatment with an active vaccine targeting alpha-synuclein
Any past or current treatment with a monoclonal antibody within the last 12 months